IGF-4: Potential Drug Target Or Biomarker (G444882)

Target Name: IGFL4

NCBI ID: G444882

IGFL4

Other Name(s): IGF like family member 4, transcript variant 1 | IGFL4 variant 1 | IGF like family member 4 | IGFL4_HUMAN | Insulin growth factor-like family member 4

IGF-4: Potential Drug Target Or Biomarker

IGF-like family member 4 (IGFL4), also known as IGF-like 4 (IGF-4), is a protein that plays a crucial role in the growth and development of tissues, including muscles, bones, and organs. It is a member of the IGF family, which consists of several similar proteins that promote growth and development by signaling through the IGF-1 receptor. IGF-4 is a potent signaling molecule, and its role in development and growth has led to its potential as a drug target or biomarker.

The IGF family of proteins consists of four isoforms: IGF-1, IGF-2, IGF-3, and IGF-4. Each isoform has a different amino acid sequence, but all contain a conserved catalytic core that is responsible for binding to the IGF-1 receptor. The IGF-1 receptor is a transmembrane protein that is expressed in various tissues throughout the body. It is composed of an extracellular portion and an intracellular portion that consists of a catalytic domain and a transmembrane region. The IGF-1 receptor is the target of many drugs that are used to treat a variety of conditions, including obesity, diabetes, and cancer.

IGF-4 is a 21-kDa protein that is predominantly expressed in skeletal muscles, heart, and liver. It is a critical regulator of muscle growth and development and has been implicated in the development and progression of several muscle-related diseases, including muscle dystrophy, myopathies, and myopathic diseases. IGF-4 is involved in the regulation of several cellular processes that are important for muscle growth and development, including protein synthesis, angiogenesis, and cell survival.

One of the key functions of IGF-4 is its ability to stimulate muscle growth and maintenance. It does this by promoting the formation of new muscle fibers and by promoting the growth of existing fibers. IGF-4 also plays a role in the regulation of muscle protein synthesis and angiogenesis, which are processes that are essential for muscle growth and development.

In addition to its role in muscle growth and development, IGF-4 is also involved in the regulation of several other cellular processes that are important for overall cellular health and function. It is a negative regulator of the unfolded protein response (UPS), which is a critical mechanism that helps to maintain the stability of intracellular proteins. IGF-4 also plays a role in the regulation of cellular apoptosis, which is the process by which cells die when they are no longer able to survive.

IGF-4 has also been shown to have potential as a drug target or biomarker in several diseases. For example, IGF-4 has been shown to be a potential therapeutic target for the treatment of cancer, particularly pancreatic cancer. Studies have shown that IGF-4 levels are often elevated in pancreatic cancer tissues, and that inhibiting IGF-4 signaling may be an effective way to treat this disease. IGF-4 has also been shown to be a potential biomarker for several diseases, including heart disease, diabetes, and liver disease.

In conclusion, IGF-4 is a protein that plays a crucial role in the growth and development of tissues, including muscles, bones, and organs. Its role in development and growth has led to its potential as a drug target or biomarker, and its effects on cellular processes are being studied in order to better understand its potential therapeutic uses. Further research is needed to fully understand the role of IGF-4 in disease and to develop effective treatments based on its properties.

Protein Name: IGF Like Family Member 4

The "IGFL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGFL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets